Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty
نویسندگان
چکیده
منابع مشابه
Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Glycoprotein IIb/IIIa antagonists are well established for their effectiveness in improving clinical outcomes in acute coronary syndrome patients undergoing percutaneous coronary intervention. Acute profound thrombocytopenia is a rare complication of abciximab. We present a case which was managed successfully for the rare complication of acute profound thrombocytopenia after using abciximab and...
متن کاملAcute profound thrombocytopenia secondary to local abciximab infusion.
Glycoprotein (GP) IIb/IIIa receptor antagonists are powerful antiplatelet agents that are typically used in percutaneous coronary intervention. All three GP IIb/IIIa agents currently approved for use in the United States cause thrombocytopenia as a rare side effect. Abciximab is unique to the class in that it is a modified monoclonal antibody to the GP IIb/IIIa receptor, a property that can lea...
متن کامل[Extreme thrombocytopenia following abciximab therapy].
Antagonists of the glycoprotein IIb/IIIa receptor block the binding of fibrinogen and Von Willebrand factor to the platelet receptor. This effect can lead to bleeding and thrombocytopenia. We analyzed the incidence and clinical repercussions of severe thrombocytopenia (< 20 000 /microl) secondary to abciximab treatment in a prospective study of 375 patients (74% men) who underwent percutaneous ...
متن کاملAcute severe thrombocytopenia after treatment with ReoPro (abciximab).
ReoPro (abciximab) is an extremely potent inhibitor of the glycoprotein IIb/IIIa receptor, the final common pathway of platelet activation and aggregation. Its main role is the maintenance of coronary patency after suboptimal results with coronary intervention. However, one of the complications of this treatment is excessive bleeding, a problem which may be compounded by a rare idiosyncratic th...
متن کاملOral anticoagulation therapy during and after coronary angioplasty.
Coronary Angioplasty To the Editor: We read with great interest the recent article by ten Berg et al1 on oral anticoagulant therapy during and after coronary angioplasty. In previous trials on late restenosis after percutaneous transluminal coronary angioplasty (PTCA), oral anticoagulants were not more effective than aspirin as adjunctive treatment after PTCA. However, in those trials, anticoag...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cardiology
سال: 1998
ISSN: 0160-9289,1932-8737
DOI: 10.1002/clc.4960211115